Rhumbline Advisers Beam Therapeutics Inc. Transaction History

Rhumbline Advisers

$103 Billion
Q1 2024

A detailed history of Rhumbline Advisers transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 109,004 shares of BEAM stock, worth $2.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

109,004

Previous 104,212 4.6%

Holding current value

$2.46 Million

Previous $2.84 Million 26.97%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$23.46 - $45.07 $112,420 - $215,975	4,792 Added 4.6%	109,004 $3.6 Million
Q4 2023 Feb 08, 2024	SELL	$17.69 - $30.76 $22,713 - $39,495	-1,284 Reduced 1.22%	104,212 $2.84 Million
Q3 2023 Nov 09, 2023	BUY	$23.01 - $32.46 $239,580 - $337,973	10,412 Added 10.95%	105,496 $2.54 Million
Q2 2023 Aug 08, 2023	BUY	$29.32 - $35.99 $209,227 - $256,824	7,136 Added 8.11%	95,084 $3.04 Million
Q1 2023 May 11, 2023	BUY	$30.15 - $48.79 $42,451 - $68,696	1,408 Added 1.63%	87,948 $2.69 Million

Q4 2022 Feb 14, 2023	BUY	$36.73 - $51.6 $58,143 - $81,682	1,583 Added 1.86%	86,540 $3.39 Million
Q3 2022 Nov 10, 2022	BUY	$39.79 - $70.31 $348,679 - $616,126	8,763 Added 11.5%	84,957 $4.05 Million
Q2 2022 Aug 11, 2022	BUY	$29.86 - $62.36 $656,681 - $1.37 Million	21,992 Added 40.57%	76,194 $2.95 Million
Q1 2022 May 12, 2022	BUY	$53.73 - $82.16 $128,360 - $196,280	2,389 Added 4.61%	54,202 $3.11 Million
Q4 2021 Feb 10, 2022	SELL	$68.02 - $99.06 $8,706 - $12,679	-128 Reduced 0.25%	51,813 $4.13 Million
Q3 2021 Nov 12, 2021	BUY	$84.37 - $133.6 $270,827 - $428,856	3,210 Added 6.59%	51,941 $4.52 Million
Q2 2021 Aug 05, 2021	BUY	$64.12 - $128.71 $322,523 - $647,411	5,030 Added 11.51%	48,731 $6.27 Million
Q1 2021 May 06, 2021	SELL	$71.28 - $120.75 $180,766 - $306,222	-2,536 Reduced 5.48%	43,701 $3.5 Million
Q4 2020 Feb 10, 2021	BUY	$22.24 - $95.63 $204,696 - $880,178	9,204 Added 24.85%	46,237 $3.78 Million
Q3 2020 Nov 12, 2020	BUY	$19.0 - $30.57 $425,334 - $684,340	22,386 Added 152.84%	37,033 $912,000
Q2 2020 Aug 13, 2020	BUY	$15.26 - $28.66 $45,078 - $84,661	2,954 Added 25.26%	14,647 $410,000
Q1 2020 May 06, 2020	BUY	$13.31 - $29.2 $155,633 - $341,435	11,693 New	11,693 $210,000

Others Institutions Holding BEAM

# of Institutions

241

Shares Held

65.6M

Call Options Held

311K

Put Options Held

777K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.59B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Beam Therapeutics Inc. Transaction History